ABBVAbbVieRunning, no new patients
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 167 (final count)
- Started
- Apr 10, 2024
- Main results expected
- Oct 2031
- Fully finished
- Oct 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Stage 1: Best Overall Response (BOR) of Complete Response (CR)/Partial Response (PR)
Measured over: Up to 21 Months
Stage 2: Overall Survival (OS)
Measured over: Up to 55 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06236438 · record last updated 2026-10-19 · checked 2026-11-09 15:47 UTC